Status:
COMPLETED
Positron Emission Tomography in Patients With Breast Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Breast Neoplasms
Eligibility:
All Genders
Brief Summary
This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical \[18F\] 2-deoxyglucose will be used as both an imaging modality and...
Detailed Description
This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical \[18F\] 2-deoxyglucose will be used as both an imaging modality and...
Eligibility Criteria
Histologically proven invasive carcinoma of the breast.
Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer who have not received local therapy to the breast or axillary lymph nodes.
Evaluable tumor, either gross or microscopic, at locoregional and/or distant sites.
No current pregnancy.
No second invasive malignancy in addition to breast cancer.
No significant concurrent medical disorders (cardiac, renal, hepatic).
Key Trial Info
Start Date :
May 1 1994
Trial Type :
OBSERVATIONAL
End Date :
April 1 2000
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00001385
Start Date
May 1 1994
End Date
April 1 2000
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892